CCO Oncology Podcast

Transforming Care in Cutaneous Squamous Cell Carcinoma: Integrating Immunotherapy Into Patient Care

Episode Summary

In this podcast, Dr David Miller and Dr Vishal Patel discuss advances in the management of cutaneous squamous cell carcinoma (cSCC), exploring how neoadjuvant and adjuvant immunotherapy is transforming treatment paradigms and highlighting patient selection, toxicity management, and emerging strategies to improve patient care.

Episode Notes

In this podcast, Dr David Miller, MD, PhD, FAAD and Dr Vishal Patel, MD discuss the evolving treatment landscape and immunotherapeutic strategies for cutaneous squamous cell carcinoma (cSCC) based on key data from pivotal studies that are reshaping standards of care, including:

• Trials of neoadjuvant immunotherapies demonstrating remarkable response rates with PD-(L)1 inhibitors such as cemiplimab, pembrolizumab, atezolizumab, and nivolumab with or without ipilimumab
• Ongoing investigational efforts, including the phase III CLEAR CSCC study of intralesional immunotherapy and radiation-immunotherapy sequencing

Presenters:

David M. Miller, MD, PhD, FAAD
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Massachusetts General Cancer Center
Assistant Professor of Medicine and Dermatology
Harvard Medical School
Boston, Massachusetts

Vishal Anil Patel, MD
Director of Cutaneous Oncology, GW Cancer Center
Director of Dermatologic Surgery, GW Department of Dermatology
Associate Professor of Dermatology & of Medicine (Hematology/Oncology)
George Washington University School of Medicine & Health Sciences
Washington, DC

Link to full program: 
https://bit.ly/3JbflO3